News

Generex is expected to continue to monitor and execute the ongoing Generex Oral-lyn study according to protocol and national/international ICH-GCPs. The study’s endpoint is for Generex Oral-lyn to

The purpose of the trial was to determine which of the various experimental formulations provided the optimum duration of drug levels in the blood. The Phase 1 trial,

Under the supply agreement, SkyPeople is expected to supply Boai with 150metric tons of Turnjujube concentrate valued at approximately $2.2m in aggregate for use in the production of

The document is designed as an aid to laboratory and facility management to simplify and facilitate the selection process but also allows evaluation of devices to identify those

According to National Pharmaceutical, an acquisition agreement is to be entered into on or before May 12 and the transaction is expected to close on or before May

Under terms of the settlement agreement, Teva has granted Watson a fully paid-up license to the US patents covering Seasonale and Watson is expected to continue marketing its

QuantRx (QN Diagnostics) claimed that this is the first distribution agreement for the company in the animal healthcare market and marks the commercial launch of its first product

Helsinn Group said that Palonosetron (palonosetron hydrochloride) is a second generation 5-HT3 Receptor Antagonist, developed for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with cancer,

Cleveland BioLabs said that CBLB502 is being developed under the FDA’s Animal Efficacy Rule to treat ARS or radiation poisoning from any exposure to radiation such as a